The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Open accessAbstract
PARP-1 is an abundant nuclear enzyme that modifies substrates by poly(ADP-ribose)-ylation. PARP-1 has well-described functions in DNA damage repair and also functions as a context-specific regulator of transcription factors. With multiple models, data show that PARP-1 elicits protumorigenic effects in androgen receptor (AR)–positive prostate cancer cells, in both the presence and absence of genotoxic insult. Mechanistically, PARP-1 is recruited to sites of AR function, therein promoting AR occupancy and AR function. It was further confirmed in genetically defined systems that PARP-1 supports AR transcriptional function, and that in models of advanced prostate cancer, PARP-1 enzymatic activity is enhanced, further linking PARP-1 to AR activity and disease progression. In vivo analyses show that PARP-1 activity is required for AR function in xenograft tumors, as well as tumor cell growth in vivo and generation and maintenance of castration resistance. Finally, in a novel explant system of primary human tumors, targeting PARP-1 potently suppresses tumor cell proliferation. Collectively, these studies identify novel functions of PARP-1 in promoting disease progression, and ultimately suggest that the dual functions of PARP-1 can be targeted in human prostate cancer to suppress tumor growth and progression to castration resistance. Significance: These studies introduce a paradigm shift with regard to PARP-1 function in human malignancy, and suggest that the dual functions of PARP-1 in DNA damage repair and transcription factor regulation can be leveraged to suppress pathways critical for promalignant phenotypes in prostate cancer cells by modulation of the DNA damage response and hormone signaling pathways. The combined studies highlight the importance of dual PARP-1 function in malignancy and provide the basis for therapeutic targeting. Cancer Discov; 2(12); 1134–49. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 1065
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“As it has been shown that DCTX affords only a modest (~2-3 month) survival advantage (52, 53), utilizing PARP-1 inhibitors as an adjuvant to DCTX may serve as a means to increase the therapeutic window in advanced disease.”
MethodPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
d'AMOURS, D., DESNOYERS, S., d'SILVA, I., & POIRIER, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,815
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,121
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Self-citationA Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription
Ju, B.-G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., & Rosenfeld, M. G. (2006) · Science · doi:10.1126/science.1127196 · Cited by 840
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.017 · Cited by 836
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Wang, Z. Q., Auer, B., Stingl, L., Berghammer, H., Haidacher, D., Schweiger, M., & Wagner, E. F. (1995) · Genes & Development · doi:10.1101/gad.9.5.509 · Cited by 774
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 687
Self-citationEl-Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 659
Kim, M. Y., Mauro, S., Gévry, N., Lis, J. T., & Kraus, W. L. (2004) · Cell · doi:10.1016/j.cell.2004.11.002 · Cited by 550
Kraus, W. L., & Lis, J. T. (2003) · Cell · doi:10.1016/s0092-8674(03)00433-1 · Cited by 546
Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure.
Poirier, G. G., de Murcia, G., Jongstra-Bilen, J., Niedergang, C., & Mandel, P. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3423 · Cited by 515
Liang, G., Lin, J. C. Y., Wei, V., Yoo, C., Cheng, J. C., Nguyen, C. T., Weisenberger, D. J., Egger, G., Takai, D., Gonzales, F. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401866101 · Cited by 484
Chromatin Loosening by Poly(ADP)-Ribose Polymerase (PARP) at Drosophila Puff Loci
Tulin, A., & Spradling, A. (2003) · Science · doi:10.1126/science.1078764 · Cited by 443
A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation
Timinszky, G., Till, S., Hassa, P. O., Hothorn, M., Kustatscher, G., Nijmeijer, B., Colombelli, J., Altmeyer, M., Stelzer, E. H. K., Scheffzek, K., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1664 · Cited by 416
Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 415
Self-citationGagné, J.-P., Isabelle, M., Lo, K. S., Bourassa, S., Hendzel, M. J., Dawson, V. L., Dawson, T. M., & Poirier, G. G. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn771 · Cited by 414
Kraus, W. L. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.03.006 · Cited by 409
Reciprocal Binding of PARP-1 and Histone H1 at Promoters Specifies Transcriptional Outcomes
Krishnakumar, R., Gamble, M. J., Frizzell, K. M., Berrocal, J. G., Kininis, M., & Kraus, W. L. (2008) · Science · doi:10.1126/science.1149250 · Cited by 381
Benjamin, R. C., & Gill, D. M. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70490-6 · Cited by 376
Poly(ADP-ribose) levels in carcinogen-treated cells
Juarez-Salinas, H., Sims, J. L., & Jacobson, M. K. (1979) · Nature · doi:10.1038/282740a0 · Cited by 348
Sharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44239 · Cited by 331
Self-citationPARP-1 Regulates Chromatin Structure and Transcription through a KDM5B-Dependent Pathway
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.014 · Cited by 326
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer
Knudsen, K. E., & Scher, H. I. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2660 · Cited by 307
Self-citationPartners in crime: deregulation of AR activity and androgen synthesis in prostate cancer
Knudsen, K. E., & Penning, T. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.002 · Cited by 293
Self-citationPARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
Brenner, J. C., Feng, F. Y., Han, S., Patel, S., Goyal, S. V., Bou-Maroun, L. M., Liu, M., Lonigro, R., Prensner, J. R., Tomlins, S. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3648 · Cited by 290
Self-citationTargeted therapy for cancer using PARP inhibitors
Lord, C. J., & Ashworth, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.016 · Cited by 289
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Self-citationPARP-1 Determines Specificity in a Retinoid Signaling Pathway via Direct Modulation of Mediator
Pavri, R., Lewis, B., Kim, T.-K., Dilworth, F. J., Erdjument-Bromage, H., Tempst, P., de Murcia, G., Evans, R., Chambon, P., & Reinberg, D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.034 · Cited by 224
Ogata, N., Ueda, K., Kagamiyama, H., & Hayaishi, O. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43873-8 · Cited by 212
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Knudsen, K. E., Arden, K. C., & Cavenee, W. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20213 · Cited by 204
Self-citationPoly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei.
Ogata, N., Ueda, K., Kawaichi, M., & Hayaishi, O. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69404-4 · Cited by 200
Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells
Berger, R., Febbo, P. G., Majumder, P. K., Zhao, J. J., Mukherjee, S., Signoretti, S., Campbell, K. T., Sellers, W. R., Roberts, T. M., Loda, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2938 · Cited by 177
Role of Glutamic Acid 988 of Human Poly-ADP-ribose Polymerase in Polymer Formation
Marsischky, G. T., Wilson, B. A., & Collier, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.7.3247 · Cited by 169
Huletsky, A., de MURCIA, G., Muller, S., Hengartner, M. O., Ménard, L., Lamarre, D., & Poirier, G. G. (1989) · PubMed · Cited by 168
Langelier, M.-F., Ruhl, D. D., Planck, J. L., Kraus, W. L., & Pascal, J. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.105668 · Cited by 167
Self-citationMertz, K. D., Setlur, S. R., Dhanasekaran, S. M., Demichelis, F., Perner, S., Tomlins, S. A., Tchinda, J., Laxman, B., Vessella, R. L., Beroukhimt, R., et al. (2007) · Neoplasia · doi:10.1593/neo.07103 · Cited by 149
Self-citationWacker, D. A., Ruhl, D. D., Balagamwala, E. H., Hope, K. M., Zhang, T., & Kraus, W. L. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01314-07 · Cited by 141
The Effect of poly(ADP-ribosyl)ation on Native and H1-depleted Chromatin
Huletsky, A., de MURCIA, G., Muller, S., Hengartner, M. O., Ménard, L., Lamarre, D., & Poirier, G. G. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81875-0 · Cited by 140
Liu, S. K., Coackley, C. L., Krause, M., Jalali, F., Chan, N. H. L., & Bristow, R. G. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.04.005 · Cited by 136
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Forster, M. D., Dedes, K. J., Sandhu, S. K., Frentzas, S., Kristeleit, R. S., Ashworth, A., Poole, C. J., Weigelt, B., Kaye, S. B., & Molife, L. R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.42 · Cited by 128
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation
Burd, C. J., Petre, C. E., Morey, L. M., Wang, Y., Revelo, M. P., Haiman, C. A., Lu, S., Fenoglio‐Preiser, C. M., Li, J., Knudsen, E. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506281103 · Cited by 125
Self-citationEvidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Centenera, M. M., Gillis, J. L., Hanson, A. R., Jindal, S., Taylor, R. A., Risbridger, G. P., Sutherland, P. D., Scher, H. I., Raj, G. V., Knudsen, K. E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0782 · Cited by 117
Self-citationLake, R. J., Geyko, A., Hemashettar, G., Zhao, Y., & Fan, H.-Y. (2010) · Molecular Cell · doi:10.1016/j.molcel.2009.10.027 · Cited by 114
Frizzell, K. M., Gamble, M. J., Berrocal, J. G., Zhang, T., Krishnakumar, R., Cen, Y., Sauve, A. A., & Kraus, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.023879 · Cited by 113
Inhibition of Nuclear Receptor Signalling by Poly(ADP-Ribose) Polymerase
Miyamoto, T., Kakizawa, T., & Hashizume, K. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2644 · Cited by 92
Böhm, M., Locke, W. J., Sutherland, R. L., Kench, J. G., & Henshall, S. M. (2009) · Oncogene · doi:10.1038/onc.2009.243 · Cited by 84
Sever-Chroneos, Z., Angus, S. P., Fribourg, A. F., Wan, H., Todorov, I., Knudsen, K. E., & Knudsen, E. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4032-4045.2001 · Cited by 74
Self-citationRelease of core DNA from nucleosomal core particles following (ADP-ribose)n-modification invitro
Mathis, G. A., & Althaus, F. R. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90358-5 · Cited by 68
Regulation of Chromatin Structure and Gene Activity by Poly(ADP-Ribose) Polymerases
Tulin, A. V., Chinenov, Y. V., & Spradling, A. C. (2003) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)01007-x · Cited by 57
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
Schiewer, M. J., Morey, L. M., Burd, C. J., Liu, Y., Merry, D. E., Ho, S., & Knudsen, K. E. (2008) · Oncogene · doi:10.1038/onc.2008.446 · Cited by 29
Self-citationOhkura, N., Nagamura, Y., & Tsukada, T. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21876 · Cited by 26
Update on radiation-based therapies for prostate cancer
Kwok, Y., & Ellsworth, S. G. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283378c84 · Cited by 14
Cited by
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
A decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
“Recently, the role of PARP1 as transcriptional regulator for nuclear factors has raised some interest, due to the role of estrogen/ progesterone and androgen receptors in breast and prostate cancer, respectively [15].”
BackgroundPARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681
“…of the effect of PARP inhibition in prostate cancer is thought to come from the dual role of PARP-1, which has been shown to regulate not only DNA damage-related pathways in prostate cancer cells but also the function of the androgen receptor as a transcriptional regulator (Schiewer et al. 2012).”
BackgroundTargeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Genomic hallmarks of localized, non-indolent prostate cancer
Fraser, M., Sabelnykova, V. Y., Yamaguchi, T. N., Heisler, L. E., Livingstone, J., Huang, V., Shiah, Y.-J., Yousif, F., Lin, X., Masella, A. P., et al. (2017) · Nature · doi:10.1038/nature20788 · Cited by 600
Metadata
- Authors
- Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., McCue, P., Gomella, L. G., Raj, G. V., Dicker, A. P., Brody, J. R., Pascal, J. M., Centenera, M. M., Butler, L. M., Tilley, W. D., Feng, F. Y., & Knudsen, K. E.
- Venue
- Cancer Discovery
- Published
- 2012-12-01
- Volume
- 2
- Issue
- 12
- Pages
- 1134-1149
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2006001375
- Cited by
- 442
- References
- 64
- FWCI
- 18.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.